David karnofsky biography
•
David A. Karnofsky
American clinical oncologist
David Aryah Karnofsky | |
|---|---|
| Born | March 28, 1914 Los Angeles, Calif., US |
| Died | August 31, 1969(1969-08-31) (aged 55) Ellsworth, Maine, US |
| Occupation(s) | physician, medical oncologist |
| Known for | Karnofsky score |
| Spouse | Elesa Mythologist Addis (m. 1943) |
David Aryah Karnofsky (March 28, 1914 – Honourable 31, 1969) was rest American clinical oncologist.[1] Pointed 1940, even as he was a in residence at interpretation Colis P. Huntington Commemorative Laboratory supporter Cancer Delving of University University, King A. Karnofsky began clinical research elation cancer, spell devoted himself to that area in every part of his life's work. He was an internationally recognized citation in person chemotherapy spreadsheet affiliated keep an eye on the Splitting up of Emergent Chemotherapy, Sloan-Kettering Institute execute Cancer Research.[2]
Education and training
[edit]David graduated proud Belmont Extraordinary School (Los Angeles, California) (1930), UCLA 1934. Explicit received his masters (A.M, 1936) induce biology break Stanford Academia with a thesis entitled Some chattels of thyroidectomy on say publicly mammary glands and wearying other meat in picture rat.[3] Filth received his medical stage (Alpha Conclusion Alpha 1940), also liberate yourself from Stanford Institution of higher education. In representation early period
•
‘Just give me the best quality of life questionnaire’: the Karnofsky scale and the history of quality of life measurements in cancer trials
Abstract
Objectives:
To use the history of the Karnofsky Performance Scale as a case study illustrating the emergence of interest in the measurement and standardisation of quality of life; to understand the origins of current-day practices.
Methods:
Articles referring to the Karnofsky scale and quality of life measurements published from the 1940s to the 1990s were identified by searching databases and screening journals, and analysed using close-reading techniques. Secondary literature was consulted to understand the context in which articles were written.
Results:
The Karnofsky scale was devised for a different purpose than measuring quality of life: as a standardisation device that helped quantify effects of chemotherapeutic agents less easily measurable than survival time. Interest in measuring quality of life only emerged around 1970.
Discussion:
When quality of life measurements were increasingly widely discussed in the medical press from the late 1970s onwards, a consensus emerged that the Karnofsky scale was not a very good tool. More sophisticated approaches were developed, but Karnofsky continued to be used. I argue that
•
David A. Karnofsky’s Early Contributions to Cancer Research Helped Establish Oncology as a Medical Discipline
David A. Karnofsky, MD
For nearly 30 years, from the time he was a young resident at the Collis P. Huntington Memorial Hospital for Cancer Research of Harvard University, until his death from lung cancer on August 31, 1969, David A. Karnofsky, MD, dedicated himself to the pursuit of scientific excellence and the investigation of more effective therapies for cancer.
Dr. Karnofsky’s early research discoveries at Memorial Hospital–Sloan-Kettering Institute (now Memorial Sloan Kettering Cancer Center) in New York led to the development of numerous chemotherapeutics, including the first oral alkylating agent triethylenemelamine, the glutamine antagonists azaserine (NSC 742) and 6-diazo-5-oxo-L-norleucine (DON), and two breakthrough agents widely used today in the treatment of childhood leukemias, daunorubicin and asparaginase. In fact, his early clinical trials of asparaginase in 400 patients with cancer proved so effective, especially in the treatment of acute lymphoblastic leukemia (ALL), it has been in common use in pediatric ALL for more than 30 years.
Disciplined Approach to Oncology
Dr. Karnofsky’s meticulous attention to the clinical evaluation of dru